$459 Million is the total value of Foresite Capital Management III, LLC's 24 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 52.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AERI | Aerie Pharmaceuticals, Inc. | $105,813,000 | -9.2% | 1,950,477 | 0.0% | 23.06% | -29.5% | |
| RCUS | New | Arcus Biosciences, Inc. | $42,080,000 | – | 3,445,461 | +100.0% | 9.17% | – |
| IMMU | Immunomedics, Inc. | $39,447,000 | -9.6% | 2,700,000 | 0.0% | 8.60% | -29.8% | |
| ALDR | Buy | Alder BioPharmaceuticals, Inc. | $37,365,000 | +14.6% | 2,942,130 | +3.3% | 8.14% | -11.0% |
| AKAOQ | Buy | Achaogen, Inc. | $36,908,000 | +44.7% | 2,850,000 | +20.0% | 8.04% | +12.4% |
| BPMC | Blueprint Medicines Corporation | $36,680,000 | +21.6% | 400,000 | 0.0% | 7.99% | -5.6% | |
| AIMT | Buy | Aimmune Therapeutics, Inc. | $29,762,000 | +2.9% | 935,020 | +22.3% | 6.49% | -20.1% |
| CBAY | Buy | CymaBay Therapeutics, Inc. | $20,291,000 | +267.6% | 1,562,040 | +160.3% | 4.42% | +185.5% |
| ASND | Sell | Ascendis Pharma A/Ssponsored adr | $19,751,000 | +46.6% | 302,009 | -10.2% | 4.30% | +13.9% |
| MYOK | Buy | Myokardia, Inc. | $19,168,000 | +49.2% | 392,789 | +28.7% | 4.18% | +15.9% |
| EPZM | Epizyme, Inc. | $17,719,000 | +41.4% | 998,278 | 0.0% | 3.86% | +9.8% | |
| VRNA | Buy | Verona Pharma Plcsponsored ads | $11,306,000 | +80.2% | 565,292 | +7.0% | 2.46% | +40.0% |
| XLRN | Acceleron Pharma Inc. | $10,899,000 | -7.9% | 278,753 | 0.0% | 2.38% | -28.5% | |
| BOLD | New | Audentes Therapeutics, Inc. | $9,476,000 | – | 315,331 | +100.0% | 2.06% | – |
| ACRS | Buy | Aclaris Therapeutics, Inc. | $5,473,000 | +4.2% | 312,368 | +46.7% | 1.19% | -19.1% |
| WVE | Sell | WAVE Life Sciences Ltd. | $3,008,000 | -47.2% | 75,000 | -53.8% | 0.66% | -59.0% |
| SGMO | New | Sangamo Therapeutics, Inc. | $2,935,000 | – | 154,462 | +100.0% | 0.64% | – |
| BHVN | Biohaven Pharmaceutical Holding Company Ltd. | $2,723,000 | -4.5% | 105,706 | 0.0% | 0.59% | -25.9% | |
| New | Achaogen, Inc.put | $2,600,000 | – | 200,000 | +100.0% | 0.57% | – | |
| SLDB | New | Solid Biosciences Inc. | $2,020,000 | – | 337,884 | +100.0% | 0.44% | – |
| TOCA | Tocagen, Inc. | $1,760,000 | +15.6% | 148,552 | 0.0% | 0.38% | -10.1% | |
| ARDX | New | Ardelyx Inc. | $1,028,000 | – | 203,592 | +100.0% | 0.22% | – |
| BDSI | New | BioDelivery Sciences International, Inc. | $338,000 | – | 150,004 | +100.0% | 0.07% | – |
| RARX | New | Ra Pharmaceuticals, Inc. | $266,000 | – | 50,000 | +100.0% | 0.06% | – |
| PACB | Exit | Pacific Biosciences of California, Inc. | $0 | – | -447,520 | -100.0% | -0.33% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Epizyme, Inc. | 24 | Q3 2021 | 17.6% |
| Acceleron Pharma Inc. | 22 | Q3 2021 | 25.9% |
| CymaBay Therapeutics, Inc. | 20 | Q3 2022 | 17.6% |
| Aerie Pharmaceuticals, Inc. | 18 | Q1 2020 | 33.5% |
| Ascendis Pharma A/S | 17 | Q3 2022 | 47.8% |
| Alder BioPharmaceuticals, Inc. | 16 | Q3 2019 | 27.4% |
| Natera, Inc. | 16 | Q3 2022 | 21.5% |
| Aimmune Therapeutics, Inc. | 16 | Q3 2019 | 8.1% |
| Verona Pharma PLC. | 15 | Q3 2022 | 30.0% |
| WAVE Life Sciences Ltd. | 15 | Q2 2019 | 20.0% |
View Foresite Capital Management III, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
| 13F-HR | 2021-11-12 |
| 4 | 2021-11-03 |
| 13F-HR | 2021-08-16 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-16 |
| 3 | 2021-02-10 |
View Foresite Capital Management III, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.